Crunch Time For 18 Products Seeking EU Approval, "No" Stays In Place for Radius
Executive Summary
Two drugs filed via the rarely-used used EU pediatric-use marketing authorization pathway are among 18 products up for an opinion from the European Medicines Agency this week on whether they should be approved. Also, Radius Health has already said its appeal has failed. What news will there be on Portola's appeal?
You may also be interested in...
OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.
OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.
Radius Braced For Second CHMP No For Abaloparatide
Another expected knockback by the European Medicines Agency's scientific committee is expected for Radius' lead product after the company revealed a negative trend vote for the osteoporosis therapy.